Abstract
Advanced cirrhosis is associated with generalized vasodilation of unknown origin, which contributes to mortality. Cirrhotic patients are endotoxemic, and activation of vascular cannabinoid CB1 receptors has been implicated in endotoxin-induced hypotension. Here we show that rats with biliary cirrhosis have low blood pressure, which is elevated by the CB1 receptor antagonist SR141716A. The low blood pressure of rats with CCl4-induced cirrhosis was similarly reversed by SR141716A, which also reduced the elevated mesenteric blood flow and portal pressure. Monocytes from cirrhotic but not control patients or rats elicited SR141716A-sensitive hypotension in normal recipient rats and showed significantly elevated levels of anandamide. Compared with non-cirrhotic controls, in cirrhotic human livers there was a three-fold increase in CB1 receptors on isolated vascular endothelial cells. These results implicate anandamide and vascular CB1 receptors in the vasodilated state in advanced cirrhosis and indicate a novel approach for its management.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Piscaglia, F. et al. Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. Eur. J. Gastroenterol. Hepatol. 9, 799–804 (1997).
Roey, G., Lijnen, P., Verbesselt, R., Verbruggen, A. & Fevery, J. Effect of narcotic agents and of bleeding on systemic and renal haemodynamics in healthy and CCl4-treated cirrhotic rats. Clin. Sci. 93, 549–556 (1997).
Chu, C-J. et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumor necrosis factor-α and nitric oxide. Clin. Sci. 93, 219–225 (1997).
Gines, P. et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 7, 122–128 (1987).
Bosch, J., Garcia-Pagán, J. C., Feu, F. & Rodés J. in The Liver: Biology and Pathobiology (eds. Arias, I.M. et al.) 1343–1355 (Raven, New York, 1994).
Wiest, R. et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J. Clin. Invest. 104, 1223–1233 (1999).
Genecin, P. & Groszman, R.J. in The Liver: Biology and Pathobiology (eds. Arias, I.M. et al.) 1327–1341 (Raven, New York, 1994)
Lumsden, A.B., Henderson, J.M. & Kutner, M.H. Endotoxin levels measured by a chromatographic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 8, 232–236 (1988).
Lin, R-S. et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 22, 165–172 (1995).
Chan, C.C. et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand. J. Gastroenterol. 32, 942–946 (1997).
Vallance, P. & Moncada, S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 337, 776–778 (1991).
Cahill, P.A. et al., Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 22, 598–606 (1995).
Sieber, C.C., Lopez-Talavera, J. C. & Groszman, R.J. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 104, 1750–1754 (1993).
Sarela, A.I., Mihaimeed, F.M.A., Batten, J.J., Davidson, B.R. & Mathie, R.T. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 44, 749–753 (1999).
Fernandez, M. et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology 108, 1487–1495 (1995).
Ryan, J., Jennings, G., Dudley, F. & Chin-Dusting, J. Smooth muscle-derived nitric oxide is elevated in isolated forearm veins in human alcoholic cirrhosis. Clin. Sci. 91, 23–28 (1996).
Mathie, R.T., Ralevic, V., Moore, K.P. & Burnstock, G. Mesenteric vasodilator responses in cirrhotic rats: a role for nitric oxide? Hepatology 23, 130–136 (1996).
Martin, P.Y. et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am. J. Physiol. 270, F494–F499 (1996).
Varga, K., Wagner, J.A., Bridgen, D.T. & Kunos, G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12, 1035–1044 (1998).
Rinaldi-Carmona, R. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240–244 (1994).
Varga, K., Lake, K., Martin, B.R. & Kunos, G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278, 279–283 (1995).
Lake, K.D., Compton, D.R., Varga, K., Martin, B.R. & Kunos, G. Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1 cannabinoid receptors. J. Pharmacol. Exp. Ther. 281, 230–237 (1997).
Knowles, R.G. & Moncada, S. Nitric oxide synthesis in mammals. Biochem. J. 298, 249–258 (1994).
Schrier, R.W. et al. Peripheral vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151–1157 (1988).
Arroyo, V. & Gines, P. Mechanism of sodium retention and ascites formation in cirrhosis. J. Hepatol. 17, S24–S28 (1993).
Garcia, N. Jr, Jarai, Z., Mirshahi, F., Kunos, G. & Sanyal, A.J. The systemic and portal hemodynamic effects of anandamide. Amer. J. Physiol. 280, G14–G20 (2001).
Martin, P-Y., Gines, P. & Schrier, R.W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N. Engl. J. Med. 339, 533–541 (1998).
Kroeger, R.J. & Groszmann, R.J. Increased portal venous resistance hinders portal pressure reduction during the administration of β-adrenergic blocking agents in a portal hypertensive model. Hepatology 5, 97–101 (1985).
Sikuler, E., Groszmann, R. J. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am. J. Physiol. 250, G205–G212 (1986),
Ledent, C. et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401–404 (1999).
Járai, Z. et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 96, 14136–14141 (1999).
Pilette, C. et al. Dose-dependent effects of nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats. J. Gastroenterol. Hepatol. 11, 1–6 (1996).
Deutsch, D.G. et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100, 1538–1546 (1997).
Sugiura, T. et al. Detection of an endogenous cannabinoid molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem. Biophys. Res. Commun. 243, 838–843 (1998).
Liu, J. et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346, 835–840 (2000).
Bilfinger, T.V. et al. Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int. J. Cardiol. 64 (Suppl. 1), S15–S22 (1998).
Wagner, J.A. et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518–521 (1997).
McCuskey, R.S., Urbaschek, R. & Urbaschek, B. The microcirculation during endotoxemia. Cardiovasc. Res. 32, 752–763 (1996).
Gebremedhin, G., Lange, A.R., Campbell, W.B., Hillard, C.J. & Harder, D.R. Cannabinoid CB1 receptor of cat cerebral arterial smooth muscle functions to inhibit L-type Ca2+ channel current. Amer. J. Physiol. 276, H2085–H2093 (1999).
Proctor, E. & Chatamra, K. High yield micronodular cirrhosis in the rat. Gastroenterology 83, 1183–1190 (1982).
Heller, S., Weber, K., Heller, A., Urbaschek, R. & Koch, T. Pentoxyfylline improves bacterial clearance during hemorrhage and endotoxemia. Crit. Care Med. 27, 756–763 (1999).
Sanyal A.J., Mirshahi, F. A simplified method for the isolation and culture of endothelial cells from pseudointima of transjugular intrahepatic portasystemic shunts. Lab. Invest. 78, 1469–1470 (1998).
Gatley, S.J. et al. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 61, 191–197 (1997).
Acknowledgements
We thank L. Chedester for assistance with cirrhotic rats. This work was supported in part by National Institutes of Health grant HL-59257 and Commonwealth of Virginia Health Research Board grant 99-04 to G.K., and grant MO-1-RR-00065-38 to the General Clinical Research Center of Virginia Commonwealth University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bátkai, S., Járai, Z., Wagner, J. et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7, 827–832 (2001). https://doi.org/10.1038/89953
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/89953
This article is cited by
-
Emerging Therapeutic Targets for Portal Hypertension
Current Hepatology Reports (2023)
-
Invasive Hemodynamic Evaluation of the Fontan Circulation: Current Day Practice and Limitations
Current Cardiology Reports (2022)
-
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications
Nature Reviews Cardiology (2021)
-
Integrating Endocannabinoid Signalling In Depression
Journal of Molecular Neuroscience (2021)
-
Hepatorenal syndrome in children: a review
Pediatric Nephrology (2021)